About the Company
Edwards Lifesciences Corporation is an American medical technology company headquartered in Irvine, California, specializing in artificial heart valves and hemodynamic monitoring. It developed the Sapien transcatheter aortic heart valve made of cow tissue within a balloon-expandable, cobalt-chromium frame, deployed via catheter. The company has manufacturing facilities at the Irvine headquarters, as well as in Draper, Utah; Costa Rica; the Dominican Republic; Puerto Rico; and Singapore; and is building a new facility completed in 2021 in Limerick, Ireland.
Sector
Industrial Applications and Services
Industry
Orthopedic, Prosthetic & Surgical Appliances & Supplies
Employees
14000
Exchange
NYSE
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest News on Edwards Lifesciences Corp
Edwards Lifesciences Corp. stock outperforms competitors on strong trading day
Shares of Edwards Lifesciences Corp. advanced 3.12% to $81.39 Wednesday, on what proved to be an all-around mixed trading ...
Nvidia, Citi, AT&T, Lucid, Edwards Sciences: What Sparked Heavy After-Hours Trading In These 5 Stocks?
The benchmark S&P 500 index fell for a fifth straight day on Thursday, with new data showing strong private sector activity ...
FTC seeks to block Edwards Lifesciences' acquisition of JenaValve
The U.S. Federal Trade Commission has sued to block Edwards Lifesciences Corp's acquisition of JenaValve Technology Inc, ...
FTC to block Edwards Lifesciences’ acquisition of JenaValve due to competitive concerns
JenaValve is obtaining FDA approval for the first transcatheter aortic valve designed to address aortic regurgitation.
Edwards announces $500M accelerated share repurchase
Irvine, California-based Edwards triggered the agreement to repurchase $500 million of its common stock. With this ...
Edwards Lifesciences: Gradually Winning My Investment Heart
Edwards Lifesciences Corporation refocuses on heart valve therapies, driving growth with innovation, FDA approvals, and ...
Edwards Lifesciences Corp. stock underperforms Tuesday when compared to competitors
This was the stock's second consecutive day of losses.
Edwards Lifesciences Corp. stock rises Monday, still underperforms ...
Shares of Edwards Lifesciences Corp. EW inched 0.43% higher to $67.19 Monday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index SPX rising 0.74% ...
FTC aims to stop Edwards' acquisition of JenaValve
The Federal Trade Commission (FTC) has moved to block Edwards Lifesciences’ purchase of JenaValve Technology and its transcatheter heart valve implant for treating aortic regurgitation, which is ...
FTC moves to block Edwards Lifesciences’ JenaValve acquisition
Edwards Lifesciences announced that the U.S. Federal Trade Commission (FTC) seeks to block its planned $1.2 billion acquisition of JenaValve.
Similar Companies
Loading the latest forecasts...